【微芯生物CHIPSCREEN是哪个国家的品牌？】

外推网助力微芯生物CHIPSCREEN品牌出海！将品牌入驻外推网，定制微芯生物CHIPSCREEN品牌推广信息，可以显著提高微芯生物CHIPSCREEN产品曝光，简直是跨境电商爆单神器！目前仅需1000元/年哦~

微芯生物是由资深留美归国团队所创立的生物高科技企业，专长于原创小分子药物研发。原创团队及本土团队在生物医学研究领域具有较高的科学造诣，有创新药研发和管理的实战经验，在欧美具有创建和管理企业的成功经历，熟知全球药品管理技术法规和专利策略，谙熟中国药品市场。

支持公司可持续发展的核心技术，是我们自主构建的基于化学基因组学的集成式药物创新与早期评价技术体系。本平台体系有效地整合了包括计算机辅助药物设计、药物及组合化学、高通量高内涵药物筛选、化学基因组学基因表达谱研究、生物信息学和化学信息学数据挖掘等多项现代技术，能有效加速小分子创新药物的研发历程、降低新药开发风险，是研发出具有临床差异化新药的重要技术，也是支撑微芯生物未来可持续发展的重要保障。

微芯生物根据国际新药研发的规律并结合中国医药市场现状，探索出了一条在保留中国产品经营权益的同时，对国际制药公司实施专利授权、建立国际临床联合开发而实现收益的企业发展之路；同时，针对性地建立与跨国制药企业高水准合作研究的商业模式。通过此发展策略，微芯生物在研创新药不仅可以尽快在中国上市销售，还能通过国际临床联合开发的模式，实现未来中国原创药进入全球市场销售的目标。这一创新发展模式——通过专利授权、合作研究和产品最终上市销售实现盈利和发展——改变了中国本土医药企业缺乏原创药这一实质性缺陷，开创了从"中国仿制"到"中国创制"的先河。

微芯生物自成立以来，围绕建立以专利和创新药物为核心竞争力的企业发展战略，在新药研发、知识产权、商务发展等方面均取得了突破性进展，已实现了多个行业领域的第一，为中国创新药物事业做出了积极贡献。

微芯生物已具备完整的从药物作用靶点研究到临床候选药物开发及产业化的能力，还成功培养出了一支在中国本土少有的专长于新化学结构体创新药物研发的技术和管理队伍，成为保障我们开发以自主知识产权为核心、针对重大疾病、有全球专利保护和临床效果独特的创新小分子化学药物及企业成长壮大的核心优势。

英文翻译：Microchip biology is a high-tech enterprise founded by a team of senior returned to the United States, specializing in the research and development of original small molecule drugs. The original team and the local team have high scientific attainments in the biomedical research field, practical experience in innovative drug R & D and management, successful experience in establishing and managing enterprises in Europe and America, familiar with global drug management technology regulations and patent strategies, and familiar with the Chinese drug market. The core technology to support the sustainable development of the company is the integrated drug innovation and early evaluation technology system based on chemical genomics that we independently build. The platform system effectively integrates a number of modern technologies, including computer-aided drug design, drug and combinatorial chemistry, high-throughput and high-content drug screening, chemical genomics gene expression profile research, bioinformatics and chemical informatics data mining, which can effectively accelerate the research and development process of small molecule innovative drugs and reduce the risk of new drug development. It is the development of clinical differences The important technology of chemical new drugs is also an important guarantee to support the future sustainable development of microchip biology. According to the law of international new drug research and development and the current situation of China's pharmaceutical market, microchip biology has explored a way for the development of enterprises that can not only retain the rights and interests of Chinese products, but also implement patent authorization for international pharmaceutical companies, establish international clinical joint development and realize profits; at the same time, establish a business model of high-level cooperative research with multinational pharmaceutical enterprises. Through this development strategy, the research and development of new drugs by micro core biology can not only be listed and sold in China as soon as possible, but also achieve the goal of China's original drugs entering the global market sales in the future through the mode of international clinical joint development. This innovative development mode - realizing profits and development through patent authorization, cooperative research and final marketing of products - has changed the substantive defect of the lack of original drugs in Chinese local pharmaceutical enterprises, and created a precedent from "Chinese imitation" to "Chinese creation". Since its establishment, micro core biology has made breakthroughs in new drug research and development, intellectual property rights, business development and other aspects around the establishment of the enterprise development strategy with patents and innovative drugs as the core competitiveness. It has achieved the first in many industries and made positive contributions to China's innovative drug industry. Micro core biology has a complete ability from drug action target research to clinical candidate drug development and industrialization, and has successfully cultivated a rare technology and management team specialized in new chemical structure innovative drug development in China, which has become the guarantee for us to develop independent intellectual property rights as the core, for major diseases, with global patent protection and unique clinical effect Special innovative small molecule chemical drugs and core advantages of enterprise growth.

本文链接： https://www.waitui.com/brand/d1f037884.html 联系电话：请联系客服添加 联系邮箱：请联系客服添加